DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Vernakalant
Vernakalant
Vernakalant Versus Ibutilide for Immediate Conversion of Recent-Onset Atrial Fibrillation Vogiatzis I, Papavasiliou E, Dapcevitch I, Pittas S, Koulouris E
Ventricular Tachycardia Drugs Versus Devices John Camm St
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Safety and Efficacy of Vernakalant for the Conversion of Atrial Fibrillation to Sinus Rhythm; a Phase 3B Randomized Controlled Trial Gregory N
FDA Briefing Document Cardiovascular and Renal Drugs
Are Atrial Human Pluripotent Stem Cell-Derived Cardiomyocytes Ready to Identify Drugs That Beat Atrial fibrillation? ✉ Torsten Christ 1,2 , Marc D
Stembook 2018.Pdf
Antiarrhythmic Medications for Cardioversion and Maintenance Of
PRAC Draft Agenda of Meeting 11-14 June 2019
(Brinavess) for the Treatment of Recent Onset Atrial Fibrillation May 2010
Australian Public Assessment Report for Vernakalant
Vernakalant in Atrial Fibrillation: a Relatively New Weapon in The
PRAC Minutes June 2019
82194326.Pdf
BRINAVESS, INN-Vernakalant Hydrochloride
Vernakalant Injection for Conversion of Recent Onset Atrial Fibrillation
Vernakalant and Electrical Cardioversion for AF – Safe and Effective
Advances in Therapy for Atrial Fibrillation
Top View
An Inventory of Medicinal Products Causing Skin Rash: Clinical and Regulatory Lessons
BRINAVESS, INN-Vernakalant Hydrochloride
Esmolol Compared with Amiodarone in the Treatment of Recent-Onset Atrial Fibrillation (Raf): an Emergency Medicine External Validity Study
Biocatalysis As Useful Tool in Asymmetric Synthesis: an Assessment of Recently Granted Patents (2014–2019)
Evaluation of the Efficacy and Safety of Different Class III Anti-Arrhythmic
Hemodynamic Effects of Vernakalant in Cardio-Surgical ICU-Patients Treated for Recent-Onset Postoperative Atrial Fibrillation
WO 2016/192680 Al 8 December 2016 (08.12.2016) P O P C T
Vernakalant NDA 22034 Resubmission Preston M
Vernakalant Dobromir Dobrev, Bashar Hamad and Peter Kirkpatrick
Vernakalant Hydrochloride in the Treatment of Atrial Fibrillation: a Review of the Latest Clinical Evidence
Reply to €˜Are Atrial Human Pluripotent Stem Cell-Derived
Atrial Flutter with 1 : 1 Atrioventricular Conduction After Administration Of
Generic Pipeline Forecast This Section Provides a Summary of Upcoming First-Time Generic Drugs and Biosimilars That May Be Approved in the Upcoming Two Years